piperacetazine (quide) Report issue

Small molecule Approved FDA
AACT ChEMBL Drug Central Drugs@FDA KEGG PubChem

Active Ingredient History

NOW
  • Now
Piperacetazine (Quide) is an antipsychotic prodrug, most notably used for schizophrenia. The study indicates that Quide is a useful addition to the armamentarium of the physician faced with the difficult problem of treating the chronic hospitalized patient with a schizophrenic illness. Side effects of the drug were generally mild, and there was no evidence that it would produce blood dyscrasias or liver impairment.   NCATS

Chemistry

  • SMILES: CC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN4CCC(CCO)CC4)C2=C1
  • InChIKey: BTFMCMVEUCGQDX-UHFFFAOYSA-N
  • Mol. Mass: 410.572
  • ALogP: 4.98
  • ChEMBL Molecule:
    piperacetazine  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

pc-1421 | pdc-1421 | piperacetazine | psymod | quide

Organizations (5)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Schizophrenia (approved 1969)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Attention Deficit and Disruptive Behavior Disorders (Phase 2)

Depressive Disorder, Major (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue